Cenobamate for the treatment of focal epilepsy
Copyright 2020 Clarivate Analytics..
Focal-onset or partial seizures are localized to a specific brain area or areas of the cerebral hemisphere. Cenobamate (CNB, Xcopri, YKP-3089; SK Life Science) is a recent U.S. Food and Drug Administration (FDA)-approved drug for the treatment of focal-onset seizures in the adult population. CNB has demonstrated broad-spectrum efficacy in alternative preclinical models of epilepsy. The molecule exerts an antiseizure effect due to its dual mechanism of action: besides inhibiting the voltage-gated persistent component of the sodium currents, CNB is additionally an allosteric GABA(A) channel modulator in a non-benzodiazepine fashion. The superior clinical effect of this molecule over placebo in reducing seizure frequency may be observed after 2 weeks following a starting oral dose of 50 mg/day. The drug can be titrated up to a maximum daily maintenance dose of 400 mg/day. CNB has mild to moderate side effects. During initial development, a critical drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome was noticed in 3 patients. However, the DRESS effect was not observed in the large C021 safety study involving 1,347 patients, suggesting a maximum potential risk of no more than 0.3%. The present monograph describes the background, preclinical and clinical pharmacology, indication and safety of CNB for the treatment of partial/focal seizures.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:56 |
---|---|
Enthalten in: |
Drugs of today (Barcelona, Spain : 1998) - 56(2020), 4 vom: 15. Apr., Seite 233-240 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Dhir, A [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 28.07.2020 Date Revised 28.07.2020 published: Print Citation Status MEDLINE |
---|
doi: |
10.1358/dot.2020.56.4.3127030 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM308945883 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM308945883 | ||
003 | DE-627 | ||
005 | 20231225132830.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1358/dot.2020.56.4.3127030 |2 doi | |
028 | 5 | 2 | |a pubmed24n1029.xml |
035 | |a (DE-627)NLM308945883 | ||
035 | |a (NLM)32309819 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Dhir, A |e verfasserin |4 aut | |
245 | 1 | 0 | |a Cenobamate for the treatment of focal epilepsy |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 28.07.2020 | ||
500 | |a Date Revised 28.07.2020 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright 2020 Clarivate Analytics. | ||
520 | |a Focal-onset or partial seizures are localized to a specific brain area or areas of the cerebral hemisphere. Cenobamate (CNB, Xcopri, YKP-3089; SK Life Science) is a recent U.S. Food and Drug Administration (FDA)-approved drug for the treatment of focal-onset seizures in the adult population. CNB has demonstrated broad-spectrum efficacy in alternative preclinical models of epilepsy. The molecule exerts an antiseizure effect due to its dual mechanism of action: besides inhibiting the voltage-gated persistent component of the sodium currents, CNB is additionally an allosteric GABA(A) channel modulator in a non-benzodiazepine fashion. The superior clinical effect of this molecule over placebo in reducing seizure frequency may be observed after 2 weeks following a starting oral dose of 50 mg/day. The drug can be titrated up to a maximum daily maintenance dose of 400 mg/day. CNB has mild to moderate side effects. During initial development, a critical drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome was noticed in 3 patients. However, the DRESS effect was not observed in the large C021 safety study involving 1,347 patients, suggesting a maximum potential risk of no more than 0.3%. The present monograph describes the background, preclinical and clinical pharmacology, indication and safety of CNB for the treatment of partial/focal seizures | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Animal models | |
650 | 4 | |a Antiepileptic drugs | |
650 | 4 | |a Cenobamate | |
650 | 4 | |a Focal seizures | |
650 | 4 | |a GABA(A) receptor modulators | |
650 | 4 | |a Neurological disorders | |
650 | 4 | |a Partial seizures | |
650 | 4 | |a Sodium channel blockers | |
650 | 7 | |a Anticonvulsants |2 NLM | |
650 | 7 | |a Carbamates |2 NLM | |
650 | 7 | |a Chlorophenols |2 NLM | |
650 | 7 | |a Tetrazoles |2 NLM | |
650 | 7 | |a Cenobamate |2 NLM | |
650 | 7 | |a P85X70RZWS |2 NLM | |
773 | 0 | 8 | |i Enthalten in |t Drugs of today (Barcelona, Spain : 1998) |d 1998 |g 56(2020), 4 vom: 15. Apr., Seite 233-240 |w (DE-627)NLM123139600 |x 1699-3993 |7 nnns |
773 | 1 | 8 | |g volume:56 |g year:2020 |g number:4 |g day:15 |g month:04 |g pages:233-240 |
856 | 4 | 0 | |u http://dx.doi.org/10.1358/dot.2020.56.4.3127030 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 56 |j 2020 |e 4 |b 15 |c 04 |h 233-240 |